Cure8 research brief
Long-term real-world data on filgotinib help patients and clinicians understand how durable benefits and risks are over 2 years, including likelihood of staying on therapy and changes in inflammation markers.
Adult patients with ulcerative colitis (especially those considering JAK inhibitors), clinicians treating UC, and researchers interested in real-world drug effectiveness and safety.
This was a retrospective cohort of 193 patients (170 included in effectiveness analyses) with median follow-up about 2 years. Drug persistence at 2 years was 50.2%. Steroid-free clinical remission was 40% at 1 year and 32% at 2 years among those with available clinical scores. CRP and faecal calprotectin remission rates at 2 years were reported around 45%.
Severe adverse events were uncommon (4.7%); two patients were diagnosed with malignancy during follow-up. The authors found that patients with proctitis and those previously exposed to advanced therapies were more likely to stop filgotinib. The report emphasizes better long-term outcomes in patients naïve to advanced therapies.
Single-centre real-world cohort with retrospective design; outcomes are persistence and biomarker remission rather than randomized trial efficacy. Structured content depth: abstract.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: UK Research and Innovation, award MR/S034919/1
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
